In November, the U.S. Department of Transportation published a final rule adding four semi-synthetic opioids -- hydrocodone, oxycodone, hydromorphone, and oxymorphone -- to the testing panel for all DOT-regulated employees. It also modified the timing for Medical Review Officers to communicate a significant safety risk or "medically unqualified" decision.
These changes go into effect January 1.
Join us for this free webinar to learn what these changes mean for you as an employer, and the seven things you need to do now to prepare your managers, drivers, and service agents.
What you'll learn:
- The seven "to-do" items to prepare for the change
- How to update your drug testing policies and job descriptions
- How to communicate the new rule to your company and DOT service agents
- The notice that you need to provide to your employees & service agents now
Continuing Education: 1.0 HRCI Credit and 1.0 SHRM Credit*